Athersys (NASDAQ:ATHX) announced today its fourth quarter 2017 and annual 2017 financial results and highlights. As quoted in the press release: “As we announced today in a separate press release, we have entered a letter of intent to expand our collaboration with Healios, and we are actively working with them with to complete the broader …

Athersys (NASDAQ:ATHX) announced today its fourth quarter 2017 and annual 2017 financial results and highlights.

As quoted in the press release:

“As we announced today in a separate press release, we have entered a letter of intent to expand our collaboration with Healios, and we are actively working with them with to complete the broader collaboration expansion by April 30, 2018, as we disclosed earlier today. In doing so, this would result in committed capital in the amount of $56.1 million, of which $31.1 million is already committed, in the form of the initial equity investment and license fee payments. Importantly, the broadened collaboration would lead to increased development of MultiStem treatment in Asia and provide us with capital to support our pivotal registration study for ischemic stroke, MASTERS-2, in the United States and Europe, as well as other important activities,” commented Dr. Gil Van Bokkelen, CEO of Athersys.

Click here to read the full press release.